Abstract

There has been intense interest in developing inhibitors of the sodium channel Na_v1.7 because genetic studies have established very strong validation for the efficacy to alleviate both inflammatory and neuropathic pain. This review summarizes patent applications targeting Na_v1.7 since 2010 until May, 2014. We have classified the patents into three categories as follows: small molecules with well-defined molecular selectivity among sodium channel isoforms; biologicals with well-defined molecular selectivity; and, small molecules that inhibit Na_v1.7 with unknown molecular selectivity. Most of the review is dedicated to small molecule selective compounds.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Cox JJ, Riemann F, Nicolas AK et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894–898 (2006).
Medline CASGoogle Scholar
2 Goldberg YP, MacFarlane J, MacDonald ML et al. Loss-of-function mutations in the Na_v1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 71, 311–319 (2007).
Medline CASGoogle Scholar
3 Dib-Hajj SD, Rush AM, Cummins TR et al. Gain-of-function mutation in Na_v1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128, 1847–1854 (2005).
Medline CASGoogle Scholar
4 Fertleman CR, Baker MD, Parker KA et al. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52(5), 767–774 (2006).
Medline CASGoogle Scholar
5 Royer A, van Veen TA, Le Bouter S et al. Mouse model of SCN5A-linked hereditary Lenegre's disease: age-related conduction slowing and myocardial fibrosis. Circulation 111(14), 1738–1746 (2005).
Medline CASGoogle Scholar
6 Bezzina CR, Shimizu W, Yang P et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction. Circulation 113(3), 338–344 (2006).
Medline CASGoogle Scholar
7 Jarvis MF, Honore P, Shieh CC et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc. Natl Acad. Sci. USA 104(20), 8520–8525 (2007).
Medline CASGoogle Scholar
8 Browne LE, Blaney FE, Yusaf SP et al. Structural determinants of drugs acting on the Na_v1.8 channel. J. Biol. Chem. 284(16), 10523–10536 (2009).
Medline CASGoogle Scholar
9 Williams BS, Felix JP, Priest BT et al. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Na_v1.7. Biochemistry 46(50), 14693–14703 (2007). • Described a series of 1-benzazepin-ones as Nav1.7 inhibitors with moderate selectivity over Nav1.5 and Nav1.8.
Medline CASGoogle Scholar
10 Bregman H, Berry L, Buchanan JL et al. Identification of potent, state-dependent inhibitors of Na_v1.7 with oral efficacy in the formalin model of persistent pain. J. Med. Chem. 54(13), 4427–4445 (2011).• Described a series of 2,4-diaminotriazines as state-dependent inhibitors of Nav1.7.
Medline CASGoogle Scholar
11 McCormack K, Santos S, Chapman ML et al. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. Proc. Natl Acad. Sci. USA 110(29), E2724–E2732 (2013).•• Described the subtype selectivity and binding sites for two highly molecularly selective inhibitors of voltage-gated sodium channels: ICA-121431 and PF-04856264.
Medline CASGoogle Scholar
12 Vertex Pharmaceuticals Inc.: WO2005013914A2 (2005).
Google Scholar
13 Icagen Inc., Pfizer Ltd: WO2010079443A1 (2010).
Google Scholar
14 Icagen Inc., Pfizer Ltd: WO2012004706A2 (2012).
Google Scholar
15 Icagen Inc., Pfizer Ltd: WO2012004743A1 (2012).
Google Scholar
16 Icagen Inc., Pfizer Ltd: WO2012004714A2 (2012).
Google Scholar
17 Nantermet PG, Henze DA. Recent advances toward pain therapeutics. Annu. Rep. Med. Chem. 46, 19–32 (2011).
CASGoogle Scholar
18 Safety And Tolerability Study Of BID Titration Scheme With PF-05089771. www.clinicaltrials.gov/show/NCT01772264
Google Scholar
19 Drug-Drug Interaction Study With PF-05089771. www.clinicaltrials.gov/show/NCT01934569
Google Scholar
20 Icagen Inc., Pfizer Ltd: WO20130057722A1 (2013).
Google Scholar
21 Xenon Pharmaceuticals Inc.: WO2013064983A1 (2013).
Google Scholar
22 Xenon Pharmaceuticals Inc.: WO2013064984A1 (2013).
Google Scholar
23 Amgen Inc.: WO2013025883A1 (2013).
Google Scholar
24 Amgen Inc.: WO2013086229A1 (2013).
Google Scholar
25 Amgen Inc.: WO2013122897A1 (2013).
Google Scholar
26 Amgen Inc.: WO2013134518A1 (2013).
Google Scholar
27 Merck Sharp & Dohme Corp.: WO2013063459A1 (2013).
Google Scholar
28 Merck Sharp & Dohme Corp.: WO2014066490A1 (2014).
Google Scholar
29 Merck Sharp & Dohme Corp.: WO2014066491A1 (2014).
Google Scholar
30 Daiichi Sankyo Company Ltd: WO2013118854A1 (2013).
Google Scholar
31 Daewoong Pharmaceutical Co. Ltd: WO 2014061970A1 (2014).
Google Scholar
32 Pfizer Ltd: WO2012007861A1 (2012).
Google Scholar
33 Pfizer Ltd: WO2012007868A2 (2012).
Google Scholar
34 Pfizer Ltd: WO2012007869A2 (2012).
Google Scholar
35 Pfizer Ltd: WO2012007877A2 (2012).
Google Scholar
36 Pfizer Ltd: WO2012007883A1 (2012).
Google Scholar
37 Pfizer Ltd: WO2012095781A1 (2012).
Google Scholar
38 Pfizer Ltd: WO2013093688A1 (2013).
Google Scholar
39 Pfizer Ltd: WO2013088315A1 (2013).
Google Scholar
40 Pfizer Ltd: WO2013102826A1 (2013).
Google Scholar
41 Pfizer Ltd: WO2012095781A1 (2012).
Google Scholar
42 Genentech, Inc; Xenon Pharmaceuticals Inc.: WO2013177224A1 (2013).
Google Scholar
43 Genentech, Inc; Xenon Pharmaceuticals Inc.: WO2014008458A2 (2014).
Google Scholar
44 Purdue Pharma L.P: WO2012004664A2 (2012).
Google Scholar
45 Purdue Pharma L.P: WO20140016673A1 (2014).
Google Scholar
46 Jassen Biotech Inc.: WO2013173706A2 (2013).
Google Scholar
47 Amgen Inc.: WO2012125973A2 (2012).
Google Scholar
48 University of Utah Research Foundation, Jassen Pharmaceutica NV: WO2013158800A1 (2013).
Google Scholar
49 Astrazeneca AB: WO2012 039657A1 (2012).
Google Scholar
50 Astrazeneca AB: WO2008130320A2 (2008).
Google Scholar
51 Kers I, Csjernyik G, Macsari I et al. Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers. Bioorg. Med. Chem. Lett. 22(17), 5618–5624 (2012).
Medline CASGoogle Scholar
52 Holenz J. Discovery and pharmacological characterization of the selective Na_v1.7 inhibitor AZD3161. Presented at: 247th National Meeting and Exposition, Dallas, TX, USA, 16–20 March 2014.
Google Scholar
53 Amgen Inc.: WO2010022055A2 (2010).
Google Scholar
54 Amgen Inc.: WO2011103196A1 (2011).
Google Scholar
55 Novartis AG: WO 2012035023 A1 (2012).
Google Scholar
56 Raqualia Pharma Inc: WO2010137351A1 (2010).
Google Scholar
57 Raqualia Pharma Inc: WO2011016234A1 (2011).
Google Scholar
58 Raqualia Pharma Inc: WO2011058766A1 (2011).
Google Scholar
59 Raqualia Pharma Inc: WO2012020567A1 (2012).
Google Scholar
60 Raqualia Pharma Inc: WO2012053186A1 (2012).
Google Scholar
61 Raqualia Pharma Inc: WO2013161308A1 (2013).
Google Scholar
62 Raqualia Pharma Inc: WO2014068988A1 (2014).
Google Scholar
63 Raqualia Pharma Inc: WO2013161312A1 (2013).
Google Scholar
64 Ilyin VI, Pomonis JD, Whiteside GT et al. Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)-phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states. J. Pharmacol. Exp. Ther. 318(3), 1–11 (2006).
MedlineGoogle Scholar
65 Purdue Pharma L.P: WO2011158108A2 (2011).
Google Scholar
66 Purdue Pharma L.P: WO2012035421A2 (2012).
Google Scholar
67 Purdue Pharma L.P: WO2012046132A1 (2012).
Google Scholar
68 Purdue Pharma L.P: WO2012007836A1 (2012).
Google Scholar
69 Purdue Pharma L.P: WO2012085650A1 (2012).
Google Scholar
70 Purdue Pharma L.P: WO2013030665 A1 (2013).
Google Scholar
71 Purdue Pharma L.P: WO2013064883A1 (2013).
Google Scholar
72 Purdue Pharma L.P: WO2013072758A1 (2013).
Google Scholar
73 Purdue Pharma L.P: WO2013136170A1 (2013).
Google Scholar
74 Purdue Pharma L.P: WO2013064884A1 (2013).
Google Scholar
75 Zalicus Pharmaceuticals Ltd: WO2011026240A1 (2011).
Google Scholar
76 Hildebrand ME, Smith PL, Bladen C et al. A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain. Pain 152(4), 833–843 (2011).
Medline CASGoogle Scholar
77 Zalicus Pharmaceuticals Ltd: WO2012116440A1 (2012).
Google Scholar
78 Zalicus Pharmaceuticals Ltd: WO2013131018A1 (2013).
Google Scholar
79 Schering Corporation: WO2010151595A1 (2010).
Google Scholar
80 Schering Corporation: WO2010151597A1 (2010).
Google Scholar
81 Schering Corporation: WO2012047703A2 (2012).
Google Scholar
82 Vertex Pharmaceuticals Inc.: WO2011140425A1 (2011).
Google Scholar
83 Vertex Pharmaceuticals Inc.: WO2012106499A1 (2012).
Google Scholar
84 Vertex Pharmaceuticals Inc.: WO2012112743A1 (2012).
Google Scholar
85 Vertex Pharmaceuticals Inc.: WO2012125613A1 (2012).
Google Scholar
86 Vertex Pharmaceuticals Inc.: WO2013067248A1 (2013).
Google Scholar
87 Vertex Pharmaceuticals Inc.: WO2013109521A1 (2013).
Google Scholar
88 Vertex Pharmaceuticals Inc.: WO2014022639A1 (2014).
Google Scholar
89 Convergence Pharmaceuticals Ltd: WO2013175206A1 (2013).
Google Scholar
90 Convergence Pharmaceuticals Ltd: WO2013/175205A1 (2013).
Google Scholar
91 Convergence Pharmaceuticals Ltd: WO2013179049A1 (2013).
Google Scholar
92 Convergence Pharmaceuticals. www.convergencepharma.com.
Google Scholar
93 Shionogi & Co. Ltd: WO2013161928A1 (2013)
Google Scholar
94 Shionogi & Co. Ltd: WO2013161929A1 (2013).
Google Scholar
95 Glaxo Group Ltd: WO2011088201A1 (2011).
Google Scholar
96 Glaxo Group Ltd: WO2013006596A1 (2013).
Google Scholar
97 GSK2339345 Hypertussive Challenge Study. www.clinicaltrials.gov/show/NCT01899768
Google Scholar
98 Gilead Sciences Inc.: WO2010002483A1 (2010).
Google Scholar
99 Gilead Sciences Inc.: WO2010053757A1 (2010).
Google Scholar
100 Gilead Sciences Inc.: WO2010056527A2 (2010).
Google Scholar
101 Gilead Sciences Inc.: WO2010056865A1 (2010).
Google Scholar
102 Gilead Sciences Inc.: WO2011056985A2 (2011).
Google Scholar
103 Gilead Sciences Inc.: WO2012003392A1 (2012).
Google Scholar
104 Gilead Sciences Inc.: WO2012154760A1 (2012).
Google Scholar
105 Gilead Sciences Inc.: WO2013006463A1 (2013).
Google Scholar
106 Gilead Sciences Inc.: WO2013006485A1 (2013).
Google Scholar
107 Gilead Sciences Inc.: WO2013043925A1 (2013).
Google Scholar
108 Gilead Sciences Inc.: WO2013112932A1 (2013).
Google Scholar
109 Peng K, Shu Q, Liu Z, Liang S. Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider Selenocosmia huwena. J. Biol. Chem. 277(49), 47564–47571 (2002).
Medline CASGoogle Scholar
110 Middleton RE, Warren VA, Kraus RL et al. Two tarantula peptides inhibit activation of multiple sodium channels. Biochem. 41(50), 14734–14747 (2002).
Medline CASGoogle Scholar

Vol. 3, No. 5

Metrics

Downloaded 457 times

History

Published online 6 November 2014

Published in print September 2014

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010

Abstract

References

Inhibitors of voltage-gated sodium channel Na_v1.7: patent applications since 2010